BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 26352094)

  • 1. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
    Corte-Rodríguez M; Espina M; Sierra LM; Blanco E; Ames T; Montes-Bayón M; Sanz-Medel A
    Biochem Pharmacol; 2015 Nov; 98(1):69-77. PubMed ID: 26352094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of cisplatin 1,2-intrastrand guanine-guanine DNA adducts in human leukocytes by high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry.
    Harrington CF; Le Pla RC; Jones GD; Thomas AL; Farmer PB
    Chem Res Toxicol; 2010 Aug; 23(8):1313-21. PubMed ID: 20666396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
    Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
    Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
    Yamada K; Kato N; Takagi A; Koi M; Hemmi H
    Anal Bioanal Chem; 2005 Aug; 382(7):1702-7. PubMed ID: 15959768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
    Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
    Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous translocation of antitumor oxaliplatin, its enantiomeric analogue, and Cisplatin from one strand to another in double-helical DNA.
    Malina J; Natile G; Brabec V
    Chemistry; 2013 Sep; 19(36):11984-91. PubMed ID: 23873652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
    Hector S; Nava ME; Clark K; Murphy M; Pendyala L
    Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin.
    Fokkema E; Groen HJ; Helder MN; de Vries EG; Meijer C
    Biochem Pharmacol; 2002 Jun; 63(11):1989-96. PubMed ID: 12093475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.
    Garmann D; Warnecke A; Kalayda GV; Kratz F; Jaehde U
    J Control Release; 2008 Oct; 131(2):100-6. PubMed ID: 18691617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3).
    Al-Shuneigat J; Qing Y; Beale P; Fisher K; Huq F
    Med Chem; 2011 Jan; 7(1):1-8. PubMed ID: 21235513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines.
    Shahsavar F; Bozorgmehr M; Mirzadegan E; Abedi A; Lighvan ZM; Mohammadi F; Safari N; Amani V; Zarnani AH
    Anticancer Agents Med Chem; 2016; 16(3):393-403. PubMed ID: 26899296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
    Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
    Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.
    Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G
    Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.